<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557518</url>
  </required_header>
  <id_info>
    <org_study_id>ALT-711-0424</org_study_id>
    <nct_id>NCT00557518</nct_id>
  </id_info>
  <brief_title>Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria</brief_title>
  <official_title>A Randomized, Placebo-Controlled Trial of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synvista Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Synvista Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based upon the preclinical evidence in models of diabetic nephropathy under conditions&#xD;
      approximating both type I and II diabetes, treatment with alagebrium appears to have&#xD;
      favorable and advantageous effects on the biochemical, structural, pathological and&#xD;
      functional hallmarks of diabetic nephropathy. The renoprotective effects of alagebrium in&#xD;
      preclinical models favor the evaluation of this drug in patients with type I diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a double-blind, randomized, placebo-controlled, parallel design trial enrolling&#xD;
      80 patients (2x40) with Type 1 diabetes and microalbuminuria. Patients will be randomized to&#xD;
      either 200 mg Alagebrium twice daily or placebo for a period of 24 weeks after an 8 week&#xD;
      run-in period. There will be a 8 week run-out period. All patients will receive ramipril&#xD;
      during the entire study period. Efficacy measurements will be performed at baseline, at 12&#xD;
      weeks and at the end of the study. Measurements for albumin:creatinine ratio(mg/g), plasma&#xD;
      renin level, collagen markers, AGE related markers and 24 hour blood pressure measurements&#xD;
      will also be determined. A total of 9 visits will be performed during the entire study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study has been terminated early due to financial constraints.&#xD;
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">November 2009</completion_date>
  <primary_completion_date type="Anticipated">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in albumin excretion rate (Âµg/min)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Albumin:creatinine ratio(mg/g), plasma renin level, collagen markers, AGE related markers, 24 hour blood pressure determinations</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alagebrium</intervention_name>
    <description>200 mg bid</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ALT-711</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>bid</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Insulin-dependent type 1 diabetes&#xD;
&#xD;
          -  Age 18-65 years&#xD;
&#xD;
          -  Diagnosis of established microalbuminuria&#xD;
&#xD;
          -  Blood pressure &lt;140 mm Hg, diastolic blood pressure &lt;90 mm Hg&#xD;
&#xD;
          -  HbA1c &lt;10%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body mass index &gt;40 kg/m2&#xD;
&#xD;
          -  Cardiovascular event within 6 months prior to screening&#xD;
&#xD;
          -  History of acute myocardial infarction within 12 months prior to screening&#xD;
&#xD;
          -  Serum creatinine &gt;1.5 mg/dL&#xD;
&#xD;
          -  Receiving chronic nonsteroidal anti-inflammatory therapy&#xD;
&#xD;
          -  Receiving antihypertensive therapy except for angiotensin converting enzyme inhibitors&#xD;
             or angiotensin receptor blockers&#xD;
&#xD;
          -  Any significant systemic illnesses,medical conditions or abnormal laboratory values&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark E Cooper, MBBS, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Baker Heart Research Institute, Melbourne, Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Diabetes Institute</name>
      <address>
        <city>Caulfield</city>
        <state>Victoria</state>
        <zip>3162</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Clinical and Biomedical Science Myers House</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelburg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steno Diabetes Center</name>
      <address>
        <city>Gentofte</city>
        <zip>DK-2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>November 12, 2007</study_first_submitted>
  <study_first_submitted_qc>November 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2007</study_first_posted>
  <last_update_submitted>January 29, 2009</last_update_submitted>
  <last_update_submitted_qc>January 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mark Cooper</name_title>
    <organization>Baker Heart Research Institute, Melbourne, Australia</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

